Search PubMed⌕ Search

Biomedical subjects

E Farrero

Publications and source records attributed to E Farrero.

5 recordsLinked to original sources
PubMed1994

Tuberculous pleural effusion: experience with six months of treatment with isoniazid and rifampicin.

BACKGROUND: Tuberculous pleurisy is associated with small numbers of bacteria. Due to the low rate of primary resistance to antituberculous drugs a two-drug regimen was used to treat the condition. METHODS: Patients received isoniazid 5 mg/kg and rifampicin 10 mg/kg daily for six months. Clinical, radiological, and haematological assessments were performed during treatment and patients were followed up for a median period of 41 (range 6-96) months. RESULTS: One hundred and thirty patients were studied with a mean age of 27 (range 11-53) years. Seven were withdrawn due to parenchymal disease and eight were lost to follow up during the treatment period. Side effects during treatment were frequent (20.7%), but only three patients required a change in medication. No treatment failures were observed. One hundred and fifteen patients completed therapy and were followed up for 41 (range 6-96) months with no evidence of a relapse. CONCLUSIONS: Tuberculous pleurisy responds well to a two-drug regimen of antituberculous therapy given for six months.

Adolescent↗
PubMedDate not supplied

Inhaled steroids treatment and withdrawal in asthmatic children.

Twenty young mild asthmatics (age range 7-22 yrs) were studied in order to determine the time course of bronchial hyperresponsiveness during inhaled steroid treatment and after steroid withdrawal. Study has been divided in three periods: Baseline (two weeks), Treatment (eight weeks) and placebo (eight weeks). Inhaled budesonide was administered during treatment period at a doses of 0.4 or 0.6 mg/ml twice a day, depending on age. After withdrawal, placebo was administered in the same way. Bronchial responsiveness (BR) to exercise was estimated trough the Bronchial Lability Index (BLI) defined as the amplitude of change of peak expiratory flow rate in a percentage related to the basal during a free running test. A BLI higher than 20% defined Bronchial Hyperresponsiveness (BHR). All patients presented BHR during the baseline period. Forced spirometry and exercise tests were performed every two weeks throughout the study. No changes in spirometric parameters (FVC, FEV1) were observed either during treatment or during placebo periods. A highly significant decrease in BR to exercise was observed during active drug treatment (BLI = 32.4 +/- 3.1 to 8.2 +/- 0.7 from basal to the end of the two months treatment period, mean +/- sd). During the placebo period 10/17 patients increased BLI to near baseline values, and 7/17 patients remained at normal levels. This behaviour was related to the severity of asthma during infancy. Our results confirm the close association between inflammation and BHR.(ABSTRACT TRUNCATED AT 250 WORDS)

Administration, Inhalation↗